June 8, 2018 10:29 AM EDT

After snatching up Shire's cancer unit, French pharma giant Servier to expand US presence with Kendall Square innovation office

Brittany Meiling

Servier, the French pharma giant that just acquired Shire’s oncology unit for $2.4 billion, is putting a US innovation outpost in Kendall Square. The new …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

After snatching up Shire's cancer unit, French pharma giant Servier to expand US presence with Kendall Square innovation office

Brittany Meiling

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

At Jefferies, all that manufacturers want to talk about is GLP-1s

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

Are programs with compounded GLP-1s safe for your population?

Af­ter snatch­ing up Shire's can­cer unit, French phar­ma gi­ant Servi­er to ex­pand US pres­ence with Kendall Square in­no­va­tion of­fice

Brittany Meiling

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

After snatching up Shire's cancer unit, French pharma giant Servier to expand US presence with Kendall Square innovation office

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Jazz wins approval for bispecific in biliary tract cancer

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

At Jefferies, all that manufacturers want to talk about is GLP-1s

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

Are programs with compounded GLP-1s safe for your population?